What's new

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

May 14, 2025 - 14:50
 0
Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Isentress, raltegravir...

Next Article

US’ a.k.a Brands posts strong Q1 2025 with $128.7 mn in net sales

Related Posts

Human medicines European public assessment report (EPAR): Aqumeldi, Enalapril maleate, Date of authorisation: 15/11/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 12, 2025  0

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

May 8, 2025  0

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

May 5, 2025  0